2024-01-01 2024-12-31 false No description of principal activity Capium Accounts Production 1.1 12112647 2024-01-01 2024-12-31 12112647 bus:FullAccounts 2024-01-01 2024-12-31 12112647 bus:FRS102 2024-01-01 2024-12-31 12112647 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 12112647 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 12112647 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 12112647 2024-01-01 2024-12-31 12112647 2024-12-31 12112647 bus:RegisteredOffice 2024-01-01 2024-12-31 12112647 core:WithinOneYear 2024-12-31 12112647 core:AfterOneYear 2024-12-31 12112647 1 2024-01-01 2024-12-31 12112647 bus:Director1 2024-01-01 2024-12-31 12112647 bus:Director1 2024-12-31 12112647 bus:Director1 2023-01-01 2023-12-31 12112647 bus:Director2 2024-01-01 2024-12-31 12112647 bus:Director2 2024-12-31 12112647 bus:Director2 2023-01-01 2023-12-31 12112647 bus:Director3 2024-01-01 2024-12-31 12112647 bus:Director3 2024-12-31 12112647 bus:Director3 2023-01-01 2023-12-31 12112647 bus:Director4 2024-01-01 2024-12-31 12112647 bus:Director4 2024-12-31 12112647 bus:Director4 2023-01-01 2023-12-31 12112647 bus:Director5 2024-01-01 2024-12-31 12112647 bus:Director5 2024-12-31 12112647 bus:Director5 2023-01-01 2023-12-31 12112647 2023-01-01 12112647 bus:LeadAgentIfApplicable 2024-01-01 2024-12-31 12112647 2023-01-01 2023-12-31 12112647 2023-12-31 12112647 core:WithinOneYear 2023-12-31 12112647 core:AfterOneYear 2023-12-31 12112647 bus:EntityAccountantsOrAuditors 2023-01-01 2023-12-31 12112647 core:PlantMachinery 2024-01-01 2024-12-31 12112647 core:PlantMachinery 2024-12-31 12112647 core:PlantMachinery 2023-12-31 12112647 core:FurnitureFittings 2024-01-01 2024-12-31 12112647 core:FurnitureFittings 2024-12-31 12112647 core:FurnitureFittings 2023-12-31 12112647 core:ComputerEquipment 2024-01-01 2024-12-31 12112647 core:ComputerEquipment 2024-12-31 12112647 core:ComputerEquipment 2023-12-31 12112647 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-12-31 12112647 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-12-31 12112647 core:CostValuation core:Non-currentFinancialInstruments 2024-12-31 12112647 core:CostValuation core:Non-currentFinancialInstruments 2023-12-31 12112647 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-12-31 12112647 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-12-31 12112647 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-12-31 12112647 core:Non-currentFinancialInstruments 2024-12-31 12112647 core:Non-currentFinancialInstruments 2023-12-31 12112647 core:ShareCapital 2024-12-31 12112647 core:ShareCapital 2023-12-31 12112647 core:RetainedEarningsAccumulatedLosses 2024-12-31 12112647 core:RetainedEarningsAccumulatedLosses 2023-12-31 12112647 dpl:AdministrativeExpenses dpl:Item1 2024-01-01 2024-12-31 12112647 dpl:AdministrativeExpenses dpl:Item1 2023-01-01 2023-12-31 12112647 dpl:AdministrativeExpenses dpl:Item2 2024-01-01 2024-12-31 12112647 dpl:AdministrativeExpenses dpl:Item2 2023-01-01 2023-12-31 12112647 dpl:Item1 2024-01-01 12112647 dpl:Item1 2024-12-31 12112647 dpl:Item1 2023-01-01 12112647 dpl:Item1 2023-12-31 iso4217:GBP xbrli:shares xbrli:pure
Logo On Report
Registered Number: 12112647
England and Wales

 

 

 

TAUC3 BIOLOGICS LIMITED



Report of the Directors and Unaudited Financial Statements
 


Period of accounts

Start date: 01 January 2024

End date: 31 December 2024
Directors Daniel Gideon CHAIN
John GOGOL
Andrew HEATH
Parag SAXENA
Shafique VIRANI
Registered Number 12112647
Registered Office 5 NEW STREET SQUARE
London
EC4A 3TW
Accountants Coulman Scott LLP
20-22 Wenlock Road
London
N1 7GU
1
Director's report and financial statements
The directors present his/her/their annual report and the financial statements for the year ended 31 December 2024
Directors
The directors who served the company throughout the year were as follows:
Daniel Gideon CHAIN
John GOGOL
Andrew HEATH
Parag SAXENA
Shafique VIRANI

This report was approved by the board and signed on its behalf by:


----------------------------------
Daniel Gideon CHAIN
Director

Date approved: 30 September 2025
2
Report to the directors on the preparation of the unaudited statutory accounts of TAUC3 BIOLOGICS LIMITED for the year ended 31 December 2024.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of TAUC3 BIOLOGICS LIMITED for the year ended 31 December 2024 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.
As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at
http://rulebook.accaglobal.com/.

This report is made solely to the Board of Directors of TAUC3 BIOLOGICS LIMITED, as a body, in accordance with the terms of our engagement letter dated 30 September 2025. Our work has been undertaken solely to prepare for your approval the accounts of TAUC3 BIOLOGICS LIMITED and state those matters that we have agreed to state to the Board of Directors of TAUC3 BIOLOGICS LIMITED, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than TAUC3 BIOLOGICS LIMITED and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that TAUC3 BIOLOGICS LIMITED has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of TAUC3 BIOLOGICS LIMITED. You consider that TAUC3 BIOLOGICS LIMITED is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of TAUC3 BIOLOGICS LIMITED. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts
31 December 2024.


Shelley Coulman
Coulman Scott LLP

20-22 Wenlock Road
London
N1 7GU
30 September 2025
3
 
 
Notes
 
2024
£
  2023
£
Turnover 125    109 
Cost of sales (339,492)   (110,717)
Gross loss (339,367)   (110,608)
Administrative expenses (512,604)   (417,618)
Operating loss 2 (851,971)   (528,226)
Interest payable and similar charges 4 (98,193)   (60,832)
Profit/(Loss) on ordinary activities before taxation (950,164)   (589,058)
Tax on profit on ordinary activities  
Profit/(Loss) for the financial year (950,164)   (589,058)
 
4
 
 
Notes
 
2024
£
  2023
£
Fixed assets      
Intangible fixed assets 5 11    11 
Tangible fixed assets 6 6,778    4,947 
6,789    4,958 
Current assets      
Debtors 7 79,341    21,558 
Cash at bank and in hand 49,041    15,153 
128,382    36,711 
Creditors: amount falling due within one year 8 (364,575)   (237,939)
Net current assets (236,193)   (201,228)
 
Total assets less current liabilities (229,404)   (196,270)
Creditors: amount falling due after more than one year 9 (2,295,497)   (1,302,648)
Net assets (2,524,901)   (1,498,918)
 

Capital and reserves
     
Called up share capital 1,581    1,581 
Profit and loss account 10 (2,526,482)   (1,500,499)
Shareholders' funds (2,524,901)   (1,498,918)
 


For the year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the board of directors on 30 September 2025 and were signed on its behalf by:


-------------------------------
Daniel Gideon CHAIN
Director
5
General Information
TAUC3 BIOLOGICS LIMITED is a private company, limited by shares, registered in England and Wales, registration number 12112647, registration address 5 NEW STREET SQUARE, London, EC4A 3TW.

The presentation currency is £ sterling.
1.

Accounting policies

Basis of preparation of Financial Statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.


The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the company's accounting policies.

The following principal accounting policies have been applied:

Going concern basis
The financial statements have been prepared on a going concern basis notwithstanding the fact that the company has a deficiency on total equity at the end of the year. The company continues to be supported by its creditors. It is currently seeking substantial external funding on the basis of the good progress made in its research projects.

Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Government grants
Grants are accounted under the accruals model as permitted by FRS 102. Grants of a revenue
nature are recognised in the profit and loss account in the same period as the related expenditure.

Research and development expenditure
Research and development expenditure is charged to the income statement in the period in which it is incurred.

Foreign currencies
Functional and presentation currency
The company's functional and presentational currency is GBP.

Transactions and balances
Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the profit and loss account within 'interest receivable and similar income' or 'interest payable and similar expenses'. All other foreign exchange gains and losses are presented in profit or loss within 'administrative expenses'.

Intangible assets
Intangible assets are initially recognised at cost. After recognition, under the cost model,
intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the
useful life cannot be made, the useful life shall not exceed ten years.


Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated
depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

The company adds to the carrying amount of an item of fixed assets the cost of replacing part of such an item when that cost is incurred, if the replacement part is expected to provide incremental future benefits to the company. The carrying amount of the replaced part is derecognised. Repairs and maintenance are charged to profit or loss during the period in which they are incurred.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and Machinery 20% Straight Line
Fixtures and Fittings 33.33% Straight Line
Computer Equipment 33.33% Straight Line
Financial instruments
The company has elected to apply the provisions of Section 11 Basic Financial Instruments and Section 12 Other Financial Instruments Issues of FRS 102 to all of its financial instruments.


Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.


Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.


The companies policies for its major classes of financial assets and financial liabilities are set out below.


Financial assets 
Basic financial assets, including trade and other debtors, cash and bank balances, intercompany working capital balances and intercompany financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.


Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.


Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.


Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.


Impairment of financial assets


Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.


For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the company would receive for the asset if it were to be sold at the reporting date.
For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.


If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.


Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.


Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.


Offsetting of financial assets and financial liabilities

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
2.

Operating profit/(loss)

2024
£
  2023
£
The operating loss is stated after charging:

 
Depreciation of tangible fixed assets 2,206    256 

3.

Average number of employees

Average number of employees during the year was 3 (2023 : 8).
4.

Interest payable and similar charges

2024
£
  2023
£
Bank & Other Loan Interest 445   
Interest Payable 97,748    60,832 
98,193    60,832 

5.

Intangible fixed assets

Cost Patents   Total
  £   £
At 01 January 2024 45,194    45,194 
Additions  
Disposals  
At 31 December 2024 45,194    45,194 
Amortisation
At 01 January 2024 45,183    45,183 
Charge for year  
On disposals  
At 31 December 2024 45,183    45,183 
Net book values
At 31 December 2024 11    11 
At 31 December 2023 11    11 


6.

Tangible fixed assets

Cost or valuation Plant and Machinery   Fixtures and Fittings   Computer Equipment   Total
  £   £   £   £
At 01 January 2024   2,600    2,603    5,203 
Additions 4,037        4,037 
Disposals      
At 31 December 2024 4,037    2,600    2,603    9,240 
Depreciation
At 01 January 2024   139    117    256 
Charge for year 471    867    868    2,206 
On disposals      
At 31 December 2024 471    1,006    985    2,462 
Net book values
Closing balance as at 31 December 2024 3,566    1,594    1,618    6,778 
Opening balance as at 01 January 2024   2,344    2,603    4,947 


7.

Debtors: amounts falling due within one year

2024
£
  2023
£
Prepayments & Accrued Income 29,904    2,897 
Other Debtors 175    14,023 
VAT Debtor 49,262    4,638 
79,341    21,558 

8.

Creditors: amount falling due within one year

2024
£
  2023
£
Trade Creditors 185,243    156,979 
Bank Loans & Overdrafts   8,439 
Amounts Owed to Group Undertakings 119,326   
PAYE & Social Security 36,849    10,186 
Accrued Expenses 17,577    43,436 
Other Creditors 4,625    16,588 
Pension Payable 955    2,311 
364,575    237,939 

9.

Creditors: amount falling due after more than one year

2024
£
  2023
£
Debenture Loans - Convertible 2,085,364    1,190,263 
Debenture Loan - Accrued interest 210,133    112,385 
2,295,497    1,302,648 

10.

Profit and loss account

  2024
£
Balance at 01 January 2024 (1,576,318)
Loss for the year (950,164)
Balance at 31 December 2024 (2,526,482)

11.

Related parties

During the year the company entered into the following transactions with related parties:
Transaction value - income/(expenses) Balance owed by/(owed to)
2024
£
 2023
£
 2024
£
 2023
£
TAU3B USA151,446 119,326 

6
  2024
£
  2023
£
Turnover          
Bank Interest   125      109 
  125      109 
Cost of sales          
Research and Development Costs 339,492      110,717 
  (339,492)     (110,717)
Gross loss   (339,367)     (110,608)
Administrative expenses          
Wages & Salaries 226,303      71,250 
Employer's PAYE & NI Contributions 23,028      8,891 
Pension Contributions 6,841      991 
Accountancy Fees 24,722      27,160 
Legal and Professional Fees (Allowable) 22,105      36,201 
Legal and Professional Fees (Disallowable)     225 
Management & Consultancy fees 148,966      189,145 
Rates & Water     3,351 
Rent 49,955      14,462 
Light, Heat & Power 2,847      310 
Cleaning of Premises 1,180     
General Travel Expenses 652      1,688 
Overseas Travel     46,485 
Bank Charges 376      589 
Bank Revaluations (650)     3,185 
Exchange Rate Losses/Gains (21,159)     (3,752)
Depreciation Charge: Plant & Machinery 471     
Depreciation Charge: Fixtures & Fittings 867      256 
Depreciation Charge: Computer Equipment 868     
Advertising 2,548      2,250 
Entertainment     4,295 
General Insurance 7,128      6,955 
Computer Expenses 7,198      2,569 
Printing, Stationery & Postage 2,270      426 
Telephone, Fax & Internet 2,425     
Sundry Expenses 192      204 
Donations     263 
Subscriptions 3,471      219 
  (512,604)     (417,618)
Operating loss   (851,971)     (528,226)
Interest payable and similar charges          
Bank & Other Loan Interest 445     
Interest Payable 97,748      60,832 
  (98,193)     (60,832)
Profit/(Loss) on ordinary activities before taxation   (950,164)     (589,058)
Profit/(Loss) for the financial year   (950,164)     (589,058)
 
7